

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

| | |
|-----------------------|----------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |

CONVEYING PARTY DATA

| Name | Execution Date |
|---------------|----------------|
| Biocept, Inc. | 06/01/2010 |

RECEIVING PARTY DATA

| | |
|-----------------|-----------------|
| Name: | Novartis AG |
| Street Address: | Lichtstrasse 35 |
| City: | Basel |
| State/Country: | SWITZERLAND |
| Postal Code: | CH-4056 |

PROPERTY NUMBERS Total: 11

| Property Type | Number |
|---------------------|----------|
| Application Number: | 11952459 |
| Application Number: | 12768388 |
| Application Number: | 61043028 |
| Application Number: | 61082169 |
| Patent Number: | 7468249 |
| Application Number: | 11277218 |
| Application Number: | 11277288 |
| Application Number: | 60953812 |
| Application Number: | 60984698 |
| Patent Number: | 5731156 |
| Patent Number: | 5962234 |

CORRESPONDENCE DATA

Fax Number: (202)842-7899
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
 Phone: 415-693-2000

CH \$440.00 11952459

Email: bhebert@cooley.com
Correspondent Name: Cooley LLP
Address Line 1: 777 6th Street, N.W., Suite 1100
Address Line 2: Patent Group
Address Line 4: Washington, DISTRICT OF COLUMBIA 20001

| | |
|-------------------------|-------------------------|
| ATTORNEY DOCKET NUMBER: | 313612-2000 ASSIGNMENTS |
|-------------------------|-------------------------|

| | |
|--------------------|----------------------|
| NAME OF SUBMITTER: | Christina MacDougall |
|--------------------|----------------------|

Total Attachments: 7
source=Biocept_to_Novartis_AG_Assignment#page1.tif
source=Biocept_to_Novartis_AG_Assignment#page2.tif
source=Biocept_to_Novartis_AG_Assignment#page3.tif
source=Biocept_to_Novartis_AG_Assignment#page4.tif
source=Biocept_to_Novartis_AG_Assignment#page5.tif
source=Biocept_to_Novartis_AG_Assignment#page6.tif
source=Biocept_to_Novartis_AG_Assignment#page7.tif

CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT

State of California

County of San Diego

On June 1, 2010 before me, Linda Macander, Notary Public

personally appeared Stephen Coultts



who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature Linda Macander

Place Notary Seal Above

OPTIONAL

Though the information below is not required by law, it may prove valuable to persons relying on the document and could prevent fraudulent removal and reattachment of this form to another document.

Description of Attached Document

Title or Type of Document: Patent Assignment


Document Date: June 1, 2010 Number of Pages: 6

Signer(s) Other Than Named Above: none

Capacity(ies) Claimed by Signer(s)

Signer's Name: Stephen Coultts


- Individual
- Corporate Officer — Title(s): President/CEO
- Partner — Limited General
- Attorney in Fact
- Trustee
- Guardian or Conservator
- Other: _____



Signer Is Representing: _____

Signer's Name: _____

- Individual
- Corporate Officer — Title(s): _____
- Partner — Limited General
- Attorney in Fact
- Trustee
- Guardian or Conservator
- Other: _____



Signer Is Representing: _____

ASSIGNMENT OF PATENT RIGHTS

- A. WHEREAS, Biocept, Inc., a corporation duly organized under and pursuant to the laws of California, and having its principal place of business at 5810 Nancy Ridge Drive, Suite 150, San Diego, CA 92121 ("Biocept"), owns the entire right, title and interest in and to (i) all Letters Patents and patent applications set forth in Exhibit A; (ii) all national stages of any international patent application identified, (iii) all other patent applications in all countries and regions claiming priority or benefit of any of the provisional or non-provisional patent application identified and all provisional and non-provisional applications in all countries and regions that were the basis of priority claims for any listed patent or application, (iv) for all patent applications, all rights of priority based upon any United States patent application identified, in all countries and regions under the Paris Convention for the Protection of Industrial Property, the Inter-American Convention relating to Inventions, Patents, Designs and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory, (v) all continuations and divisions of any United States patent application or international application identified, any national stages of any international application identified and any patent applications within the scope of (iii) (including further continuations and divisions such as, but not limited to, continuations of continuations and continuations of divisions), (vi) all patents that are granted on any of said patent applications, (vii) all registrations and confirmations of, and importation certificates based upon, one or more of said patents and applications for such registrations, confirmations and importation certificates, and (viii) all reissues, renewals, extensions, reexamination certificates, supplementary protection certificates of said patents, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates (collectively paragraphs (i) through (viii) are herein referred to as "Patents").
- B. WHEREAS, Novartis AG, a corporation of Switzerland having a place of business at Lichtstrasse 35, CH-4056, Basel, Switzerland ("Novartis AG"), is desirous of acquiring an undivided ownership in the right, title, and interest in and to said Patents;
- C. WHEREAS, pursuant to that certain Patent Assignment Agreement (the "Assignment Agreement") entered into by Biocept and Novartis Vaccines and Diagnostics, Inc., Biocept has agreed to execute and deliver this assignment to Novartis Vaccines and Diagnostics, Inc.

NOW THEREFORE, in partial consideration of the amounts paid by Novartis Vaccines and Diagnostics, Inc. pursuant to the Assignment Agreement and other good and valuable consideration,

1. Biocept hereby sells, assigns, transfers and sets over unto Novartis AG the entire right, title and interest in and to the Patents, which Patents shall be held and enjoyed by Novartis AG for its own use, and for the use of its legal representatives, successors and assigns, to the full end

of the term for which the Patents are granted, as fully and entirely as the same would have been held by Biocept had this assignment, sale and transfer not been made.

2. Biocept authorizes and requests the Commissioner of Patents of the United States of America and the empowered officials of all other governments to issue or transfer all such Patents to Novartis AG, as assignee of its entire right, title and interest therein, or otherwise as Novartis AG may direct.

Executed this [1] day of [June], [2010].

BIOCEPT, INC.

SM Coutts

By: Stephen M. Coutts

Its: President & CEO

Exhibit A

| DOCKET No. | FILING DATA | PRIORITY DATE |
|-------------------|--|----------------------|
| BIOE-009/01US | US 20080176237 11/952,459 filed 12/07/2007 Noninvasive Prenatal Genetic Screen | 12/07/06 |
| BIOE-009/02US | 12/768,388 filed 04/27/2010 Noninvasive Prenatal Genetic Screen | 12/07/06 |
| BIOE-009/01WO | WO 2008/070862 PCT/US2007/086862 Noninvasive Prenatal Genetic Screen National Phase Application filed in EP | 12/07/06 |
| BIOE-009/01EP | EP 2140027 EP 07869055.9, filed 10/23/2009 Noninvasive Prenatal Genetic Screen | 12/07/06 |
| BIOE-015/00US | 61/028,064 filed 02/12/2008 Method for Isolating Cell Free Apoptotic or Fetal Nucleic Acids | 02/12/08 |
| BIOE-015/01WO | WO 2009/102632 PCT/US2009/33375 filed 02/06/2009 Isolation of Circulating Fetal DNA from Maternal Blood for Fetal Genetic Testing | 02/12/08 |
| BIOE-016/00US | 61/043,028 filed 04/07/2008 Device Utilizing Electric Field and Size Cut-Off for the Separation of Charged Species | 04/07/08 |
| BIOE-017/00US | 61/082,169 filed 07/18/2008 Non-Invasive Fetal RhD Genotyping from Maternal Whole Blood | 07/18/08 |
| BIOE-017/01WO | WO 2010/009440 PCT/US2009/51061, filed 07/17/2009 Non-Invasive Fetal RhD Genotyping from Maternal Whole Blood | 07/18/08 |
| BIOE-018/00US | 61/024,872 filed 01/30/2008 Two-Stage Enrichment of Cell-Free Fetal DNA in Maternal Plasma | 01/30/08 |
| BIOE-018/01WO | WO 2009/097511 PCT/US2009/32614 filed 01/30/2009 Two-Stage Enrichment of Cell-Free Fetal DNA in Maternal Plasma | 01/30/08 |
| | US Patent No. 7,468,249 (Issued 12/23/2008) Detection of Chromosomal Disorders | 05/05/2004 |
| | WO 2005/111237 PCT/US2005/013070 filed 04/18/2005 Detection of Chromosomal Disorders National Phase applications filed in EP, CN, JP, KR | 05/05/2004 |

| DOCKET No. | FILING DATA | PRIORITY DATE |
|------------|---|---------------|
| | EP 1759011 A EP 05740284.4 filed 12/04/2006 Detection of Chromosomal Disorders | 05/05/2004 |
| | IN 4473/CHENP/2006 filed 04/18/2005 Detection of Chromosomal Disorders | 05/05/2004 |
| | JP 2007-511389 filed 04/18/2005 Detection of Chromosomal Disorders | 05/05/2004 |
| | KR 7025434/2006 filed 04/18/2005 Detection of Chromosomal Disorders | 05/05/2004 |

| DOCKET No. | FILING DATA | PRIORITY DATE |
|---------------|---|---------------|
| BIOE-003/00US | US 20070224588 11/277,218 filed 03/22/2006 Trophoblast Preservation/Pretreatment Medium and Method | 03/22/06 |
| BIOE-004/00US | US 20070224597 11/277,288 filed 3/23/2006 Isolating Fetal Trophoblasts | 03/23/06 |
| BIOE-004/01WO | WO 2007/112281 PCT/US07/64705 filed 03/22/2007 Isolating Fetal Trophoblasts | 03/23/06 |
| BIOE-004/01EP | 07759181.6 | 3/23/06 |
| BIOE-004/01IN | 3861/KOLNP/2008 | 3/23/06 |
| BIOE-004/01JP | 2009-501741 | 3/23/06 |
| BIOE-004/01KR | 10-2008-7025832 | 3/23/06 |
| BIOE-013/00US | 60/953,812 filed 8/3/2007 In-Situ Hybridization to Detect RNA and DNA Markers | 08/03/07 |
| BIOE-013/01US | 12/671,902, filed 02/02/2010 In-Situ Hybridization to Detect RNA and DNA Markers | 08/03/07 |

| DOCKET No. | FILING DATA | PRIORITY DATE |
|---------------|---|---------------|
| BIOE-013/01WO | WO 2009/020932 PCT/US2008/072143 filed 08/04/2008 In-Situ Hybridization to Detect RNA and DNA Markers National Phase Applications filed in AU- application filed 2008284024 BR- application filed PI0814988-7 CA- application filed 2,695,369 CN- application filed, awaiting filing details EG- application filed PCT173/2010 EP- application filed 08797146.1 IL- application filed 203673 JP- application filed, awaiting filing details KR- application filed 10-2010-7004769 MX- application filed MX/a/2010/001380 NZ- application filed 583365 UA- application filed 201002384 ZA- application filed 2010/00836 | 08/03/07 |
| BIOE-014/00US | 60/984,698 filed 11/01/2007 Non-Invasive Isolation Of Fetal Nucleic Acid | 11/01/07 |
| BIOE-014/01US | 12/740,418 filed 04/29/2010 Non-Invasive Isolation Of Fetal Nucleic Acid | 11/01/07 |
| BIOE-014/01WO | WO 2009/058997 PCT/US2008/81780 filed 10/30/2008 Non-Invasive Isolation Of Fetal Nucleic Acid | 11/01/07 |
| BIOE-021/00US | U.S. Patent No. 5,731,156 (Issued 3/24/98) Use of Anti-Embryonic Hemoglobin Antibodies to Identify Fetal Cells | 10/21/96 |
| BIOE-021/01US | U.S. Patent No. 5,962,234 (Issued 10/5/99) Use of Anti-Embryonic Hemoglobin Antibodies to Identify Fetal Cells | 10/21/96 |
| BIOE-021/01WO | PCT/US97/019447 filed 10/20/97 Use of Anti-Embryonic Hemoglobin Antibodies to Identify Fetal Cells | 10/21/96 |
| BIOE-021/01EP | EP 1007965 B1 Use of Anti-Embryonic Hemoglobin Antibodies to Identify Fetal Cells | 10/21/96 |
| BIOE-021/01DE | EP 1007965 B1 Use of Anti-Embryonic Hemoglobin Antibodies to Identify Fetal Cells | 10/21/96 |
| BIOE-021/01FR | EP 1007965 B1 Use of Anti-Embryonic Hemoglobin Antibodies to Identify Fetal Cells | 10/21/96 |

| DOCKET No. | FILING DATA | PRIORITY DATE |
|-------------------|--|----------------------|
| BIOE-021/01GB | EP 1007965 B1 Use of Anti-Embryonic Hemoglobin Antibodies to Identify Fetal Cells | 10/21/96 |
| BIOE-021/01CH | EP 1007965 B1 Use of Anti-Embryonic Hemoglobin Antibodies to Identify Fetal Cells | 10/21/96 |
| BIOE-021/01IT | EP 1007965 B1 Use of Anti-Embryonic Hemoglobin Antibodies to Identify Fetal Cells | 10/21/96 |
| BIOE-021/01AU | AU 735380 (Issued 10/18/01) 49200/97 Use of Anti-Embryonic Hemoglobin Antibodies to Identify Fetal Cells | 10/21/96 |
| BIOE-021/01BR | 97/19447 Use of Anti-Embryonic Hemoglobin Antibodies to Identify Fetal Cells | 10/21/96 |
| BIOE-021/01CA | 2,269,327 Use of Anti-Embryonic Hemoglobin Antibodies to Identify Fetal Cells | 10/21/96 |
| BIOE-021/01CN | 97199005.0 Use of Anti-Embryonic Hemoglobin Antibodies to Identify Fetal Cells | 10/21/96 |
| BIOE-021/01HK | 00108086.8 Use of Anti-Embryonic Hemoglobin Antibodies to Identify Fetal Cells | 10/21/96 |
| BIOE-021/01IL | 129382 (Issued 12/15/02) Use of Anti-Embryonic Hemoglobin Antibodies to Identify Fetal Cells | 10/21/96 |
| BIOE-021/01JP | JP 4091123 (Issued 3/7/08) 10-519694 Use of Anti-Embryonic Hemoglobin Antibodies to Identify Fetal Cells | 10/21/96 |
| BIOE-021/01KR | KR 523381 (Issued 10/15/05) 1999-7003439 Use of Anti-Embryonic Hemoglobin Antibodies to Identify Fetal Cells | 10/21/96 |
| BIOE-021/01MX | MX 222443 (Issued 9/1/04) Use of Anti-Embryonic Hemoglobin Antibodies to Identify Fetal Cells | 10/21/96 |
| BIOE-021/01RU | RU 2178703 (Issued 1/27/02) Use of Anti-Embryonic Hemoglobin Antibodies to Identify Fetal Cells | 10/21/96 |
| BIOE-021/02IL | IL 145691 (Issued 11/2/03) Use of Anti-Embryonic Hemoglobin Antibodies to Identify Fetal Cells | 10/21/96 |